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Basal and LPS-stimulated inflammatory markers
and the course of individual symptoms of
depression
Wessel A. van Eeden 1, Albert M. van Hemert1, Ingrid V. E. Carlier1, Brenda W. J. H. Penninx2,3, Femke Lamers2,3,
Eiko I. Fried4, Robert Schoevers5 and Erik J. Giltay1
Abstract
Multiple studies show an association between inflammatory markers and major depressive disorder (MDD). People
with chronic low-grade inflammation may be at an increased risk of MDD, often in the form of sickness behaviors. We
hypothesized that inflammation is predictive of the severity and the course of a subset of MDD symptoms, especially
symptoms that overlap with sickness behavior, such as anhedonia, anorexia, low concentration, low energy, loss of
libido, psychomotor slowness, irritability, and malaise. We tested the association between basal and lipopolysaccharide
(LPS)-induced inflammatory markers with individual MDD symptoms (measured using the Inventory of Depressive
Symptomatology Self-Report) over a period of up to 9 years using multivariate-adjusted mixed models in 1147–2872
Netherlands Study of Depression and Anxiety (NESDA) participants. At baseline, participants were on average 42.2
years old, 66.5% were women and 53.9% had a current mood or anxiety disorder. We found that basal and LPS-
stimulated inflammatory markers were more strongly associated with sickness behavior symptoms at up to 9-year
follow-up compared with non-sickness behavior symptoms of depression. However, we also found significant
associations with some symptoms that are not typical of sickness behavior (e.g., sympathetic arousal among others).
Inflammation was not related to depression as a unified syndrome but rather to the presence and the course of
specific MDD symptoms, of which the majority were related to sickness behavior. Anti-inflammatory strategies should
be tested in the subgroup of MDD patients who report depressive symptoms related to sickness behavior.
Introduction
Inflammatory markers and depression have an intricate
and complex relationship1,2. Evidence from meta-analyses
suggests that depressed subjects have higher circulating
concentrations of acute-phase proteins and pro-
inflammatory cytokines compared with healthy sub-
jects3–8. During an inflammatory response, the innate and
adaptive immune systems are activated. Pro-inflammatory
cytokines are produced by macrophages, monocytes, and
other cells that stimulate the liver to produce acute-phase
proteins. Chronically increased levels of peripheral blood
interleukin (IL-6), tumor necrosis factor-alpha (TNF-α),
and C-reactive protein (CRP), all of which indicate low-
grade inflammation, are often associated with depression1.
Other studies, however, have not found significant
associations7,8.
Another approach to assess inflammation is to stimu-
lating the immune cells and study the clinically important
immune disturbances9,10. After ex vivo induction of
lipopolysaccharide (LPS: the cell membrane of Gram-
negative bacteria that strongly induces immunological
responses) in whole blood samples, a wide array of
pro-inflammatory cytokines are released, which can be
measured in the supernatant9,10. Fewer studies exist on
© The Author(s) 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Wessel A.van Eeden (W.A.van_Eeden@lumc.nl)
1Department of Psychiatry, Leiden University Medical Center, Leiden, The
Netherlands
2Department of Psychiatry, Amsterdam Public Health Research Institute,
Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands


































LPS-induced inflammation’s putative importance for
depression11–13. Previous studies have found an associa-
tion between LPS-stimulated inflammatory markers and
depression. Sum scores of the Beck’s depression inventory
were associated with higher levels of inflammatory mar-
kers interleukin-1beta (IL-1β), tumor necrosis factor-
alpha (TNF-α), and interleukin-8 (IL-8), after LPS
induction in whole blood. In addition, depressed men had
higher monocyte chemoattractant protein-1 (MCP-1)
levels, and depressed women had higher IL-1α levels11,12.
In a previous cross-sectional analysis of the NESDA
cohort, higher levels of LPS-induced inflammatory mar-
kers were found among patients with a remitted or cur-
rent depression compared with healthy controls13. LPS-
induced inflammatory markers were especially elevated
among MDD patients with the DSM-5 anxious distress
specifier14. Results remained statistically significant for
LPS induced but not for basal levels of inflammatory
markers, after adjusting for lifestyle and somatic health-
related covariates13.
Researchers have speculated on the existence of cross-
talk between several inflammatory pathways and neuro-
circuits that may lead to sickness behavior1,15,16. Sickness
behavior as a syndrome is still rather ill-defined and has
varied across time, disciplines, and studies but is generally
regarded as an organized group of reward oriented
behavioral and motivational changes that accompany
inflammation and infections1,15,17,18. Researchers have
theorized that sickness behavior holds some evolutionary
advantages and has protective mechanisms for the indi-
vidual (e.g., recovery), because it preserves energy
resources needed for healing infection or other diseases
and may help prevent the transmission of its potential
infectious agent1,18. The causal chain may involve
somatic triggers inducing an inflammatory response fol-
lowed by sickness behavior. Sickness behavior in turn
overlaps with and induces depression, with additional
positive feedback loops between (neuro) inflammation
and (neuro) degenerative processes1,16,18. Sickness beha-
vior symptoms show a considerable overlap with
depressive symptoms like anhedonia, anorexia, low con-
centration, low energy, low libido, psychomotor slowness,
irritability; and researchers have hypothesized that
depression is a maladaptive or exacerbated form of
sickness behavior in some patients with chronic low-
grade inflammation15–20. Besides their reward-sensitivity
related symptoms, recent studies suggest that also
trauma- and anxiety-related symptoms are related to
inflammatory markers, resulting in a mix of overlapping
symptoms of mood, anxiety, and post-traumatic stress
disorder13,21–23. A causal pathway in which inflammation
causes symptoms of anxiety is less established as studies
show that inflammatory levels increase when study par-
ticipants became anxious24,25, and a large longitudinal
study found that anxiety predicted inflammation in the
future but not vice versa26.
Inflammatory markers and depression have been linked,
but effect sizes were generally small with limited clinical
relevance for the individual patient1. Because depression
is a heterogeneous disorder with large between-person
variation27 and symptomatology28,29, low-grade inflam-
mation may only be strongly linked to a subset of
depressive symptoms30,31. Thus, inflammation may be
involved in the pathogenesis of a subset of MDD patients.
Identifying associations between pro-inflammatory mar-
kers and specific depressive symptoms could advance
personalized medicine32. Nevertheless, few clinical studies
have analyzed whether inflammatory markers are asso-
ciated with specific MDD symptoms30,32–34.
Inflammation has been repeatedly linked to sickness-
behavior symptoms such as certain sleeping problems,
low energy, changes in appetite, low mood, and cognitive
symptoms30,32–34. Two recent cross-sectional analyses in
the current NESDA cohort found that inflammatory
markers demonstrated the strongest associations with
sleep and energy level, appetite/weight, and aches and
pains, but associations were reduced or disappeared
completely when adjusted for demographic-, lifestyle-,
and disease-related factors such as BMI, activity, chronic
somatic diseases, and gender30,31. Adjusting for certain
variables is necessary in order to avoid confounding.
However, overadjustment must also be avoided as vari-
ables such as activity, BMI, and somatic diseases may be
part of the causal pathway between low-grade inflamma-
tion (which could be induced by somatic disease) on the
one hand, and sickness behavior (which includes reduced
activity and anorexia) and depression on the other
hand15,17–20. There is still no consensus in the field about
how to approach these demographic, somatic and lifestyle
variables, and studies show that taking these variables into
account as either confounders, or as part of the causal
pathway, greatly influences the effect size of the relation
between inflammation and depression35. We are not
aware of previous studies that examined the symptom-
specific associations with LPS-induced inflammatory
agents. Moreover, examining individual symptoms long-
itudinally is important as inflammation may be related
differently to depression symptoms longitudinally36–40. A
recent longitudinal study for example found that inflam-
mation was especially related to atypical symptoms40.
Moreover, one meta-analysis demonstrated that increased
inflammation can be associated with the development of
late-life and the persistence of depression39. The present
study extends on the current literature as we examined
associations between basal levels and LPS-induced
inflammatory markers and individual MDD symptoms
in a large cohort over the course of 9 years. We hypo-
thesized that persistent low-grade inflammation will show
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the strongest associations with symptoms characteristic of
sickness behavior.
Methods and materials
Study sample and procedures
We evaluated baseline and follow-up data from 2872
out of 2981 participants from the NESDA cohort. NESDA
investigated the course and consequences of depressive
and anxiety disorders. NESDA included patients and
healthy controls from a diverse array of (health-care)
settings and applied a limited number of exclusion cri-
teria, namely not being fluent in Dutch and the presence
of other clinically overt psychiatric disorders (e.g., addic-
tion, psychotic, and bipolar). With this method, NESDA
aimed for a cohort that is representative for diverse
populations of healthy controls and patients with
depression and anxiety41. The first measurement wave
(baseline) ran from 2004 to September 2007; the sixth
wave at the 9-year follow-up finished in October 2016. All
procedures involving human subjects/patients were
approved by Ethical Review Board of the VU University
Medical Centre and subsequently by local review boards
of each participating center. Written informed consent
was obtained from all participants. Where verbal consent
was obtained this must be followed by a statement such
as: Verbal consent was witnessed and formally recorded.
More detailed design and sampling procedures are pub-
lished elsewhere41. Basal serum levels of inflammatory
markers were collected from 2867 participants. For logistical
reasons, LPS induction in blood was only assessed during
the last year of baseline sample collection. Consequently,
data of LPS-stimulated inflammatory markers were available
from 1229 out of 2867 participants. Of all the demographics
and clinical characteristics mentioned in Table 1, this sub-
selection did not differ from participants with missing data
(p > 0.05), with the exception of age because the LPS sub-
group was on average 1 year older. About 40% of the sample
had a chronic somatic disease. A wide variety of diseases
were assessed through a self-report questionnaire, asking for
the presence of 20 common chronic diseases including
asthma, chronic bronchitis or pulmonary emphysema, heart
diseases or infarct, diabetes, stroke or CVA, arthritis or
arthrosis, rheumatic complaints, tumor and/or metastasis,
stomach or intestinal disorders, liver disease or liver cir-
rhosis, epilepsy, thyroid gland disease, or another chronic
disease for which the patient receives treatment. A count
was made of the number of chronic diseases for which a
person reported receiving treatment. More details regarding
this variable can be found elsewhere42.
Measures
Demographics and clinical features
The Composite International Diagnostic Interview
(CIDI WHO, version 2.1) was used to assess the presence
of depressive and anxiety disorders according to the
DSM-IV. The CIDI is a fully standardized diagnostic
interview with validated psychometric characteristics41,43.
Demographic variables were described and included
gender, age, ethnicity (yes/no regarding Northern Eur-
opean heritage), and level of education (elementary or
less; general intermediate/secondary education; college/
university). Patients also indicated whether they had a
fever or cold in the week prior to blood draw (sickness
prior to interview).
Medication use was determined by inspecting partici-
pants’ medication containers. Antidepressant use inclu-
ded selective serotonin reuptake inhibitors (SSRIs; ATC
code: N06AB), tricyclic antidepressants (TCAs; ATC
code: N06AA), and other antidepressants (ATC codes:
N06AF, N06AG, N06AX). The use of statins (ATC code:
C10AA) and anti-inflammatory, anti-rheumatic, and anti-
allergic medications (ATC codes: M01A, M01B, A07EB,
A07EC) was also assessed (further referred to as anti-
inflammatory medication).
Independent variables: inflammatory markers
Baseline inflammatory markers CRP, IL-6, and TNF-α
were assessed using fasting blood plasma levels (see the
Supplementary information). Intra- and inter-assay coef-
ficients of variation for CRP levels were 5% and 10%,
respectively. Intra- and inter-assay coefficients of variation
for IL-6 levels were 8% and 12%, respectively. Intra- and
inter-assay coefficients of variation for TNF-α levels were
10% and 15%, respectively.
Inflammation is likely to occur when multiple cytokines
are elevated. We did not form specific hypotheses about
individual inflammatory markers, so we created a basal
inflammation index, representing the mean value of loge-
transformed (due to non-normality) and standardized
levels of CRP, IL-6, and TNF-α13.
Independent variables: inflammatory markers after LPS
induction
The innate immune response of 12 cytokines was
assessed in ex vivo stimulated blood using LPS (see the
Supplementary information). For all available samples, we
simultaneously assessed levels of interferon-γ (IFN-γ),
macrophage inflammatory protein-α (MIP-1α), IL-2, IL-6,
IL-8, IL-10, IL-18, MCP-1, macrophage inflammatory
protein-α (MIP-1α), MIP-1β, matrix metallopeptidase-2
(MMP-2), TNF-α, and TNF-β using a multi-analytic
profile (Human CytokineMAP A v.1.0; Myriad RBM,
Austin, TX, USA). Cytokine distributions were skewed to
the right and therefore loge-transformed to normalize
their distributions.
We created an LPS-induced inflammation index com-
posed from the mean standardized value of all available
LPS-induced markers, further referred to as LPS-induced
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inflammation index. To avoid loss of information, we
conducted an exploratory factor analysis EFA44; which
resulted into two LPS-induced inflammation indexes,
further referred to as LPS-induced inflammation index-1
and LPS-induced inflammation index-2. Markers IFN-γ,
IL-10, IL-2, IL-6, MMP-2, TNF-α, and TNF-β loaded on
LPS-induced inflammation index-1 with factor loadings
between 0.41 and 0.88 and a raw alpha of 0.86. IL-8, IL-18,
MCP-1, MIP-1α, and MIP-1β loaded on LPS-induced
inflammation index-2. See Supplementary information for
the correlations between individual markers within each
index (Supplementary information Fig. 1) and a more
detailed description of the EFA procedures. Subsequently,
two LPS-induced inflammation indexes were calculated as
the mean of loge-transformed and standardized markers.
Dependent variables: IDS items
The sum score of the Inventory of Depressive Symp-
tomatology Self-Report (IDS-SR) was used as the outcome
measure for severity and course of depression on syn-
drome level, and the separate items were used for the
symptom analyses45,46. The IDS-SR consists of 30 equally
weighted items, rated on a 4-point Likert scale (0–3), and
includes all symptoms of depression: melancholic, atypi-
cal, and anxious symptoms. Several additional symptoms
were included: sympathetic arousal, pessimism, and
interest in sex. We hypothesized that the following 16
IDS-SR items would be associated with inflammation at
baseline because they can identify sickness-behavior
symptoms:15,17–20 sleeping too much (Item 4), feeling
irritable (Item 6), responsiveness of mood (Item 8),
decrease in appetite (Item 11), decrease in weight (Item
12), concentration (Item 15), pessimism (Item 17), general
interest (Item 19), low energy level (Item 20), capacity for
pleasure (Item 21), interest in sex (Item 22), psychomotor
retardation (Item 23), aches and pains (Item 25), sympa-
thetic arousal (Item 26), constipation or diarrhea (Item
28), and leaden paralysis (Item 30).
Statistical analysis
We used a multivariate linear mixed model with IDS-SR
item-scores as outcome variables and inflammatory
markers as the main independent variables. Because of the
heterogeneity of our sample (healthy and depressed par-
ticipants at baseline), the intercepts and slopes were
considered as random variables, which resulted in a sig-
nificantly better fit compared with a nonrandom model.
(For the model with the basal inflammation index, the log
likelihood (LL)-ratio increased by 80932.5, p < 0.001; for
LPS-induced inflammation index-1, LL-ratio increased by
36887.2, p < 0.001; and for LPS-induced inflammation
index-2, LL-ratio increased by 38640.1, p < 0.001.) Adding
an interaction between time and inflammatory markers
resulted a minimal increase of model fit. (For the model
with the basal inflammation index, the LL-ratio increased
by 12.2, p < 0.001; for LPS-induced inflammation index-1,
the LL-ratio increased by 1.9, p= 0.167; and for LPS-
induced inflammation index-2, the LL-ratio increased by
12.5, p < 0.001.) This small effect could be attributed to
regression to the mean, so we decided not to include the
interaction terms in our final models. Doing so resulted in
mixed models for each individual IDS item with random
intercepts and slopes over time, that analyzed whether
participants with elevated levels of inflammation were
more likely to have higher symptom levels at baseline and
during the 9-year follow-up period. Models were adjusted
for certain baseline variables: gender, age, sickness prior
to interview, and the use of anti-inflammatory medication.
In sensitivity analyses, we repeated the analysis for MDD
patients (~30% of the total sample; Supplementary
information Table 1 and Supplementary information Fig.
2) and for the LPS-inflammatory composite index score
(Supplementary information Table 2 and Supplementary
information Fig. 3). Moreover, sensitivity analyses were
executed which additionally adjusted for chronic somatic
diseases and antidepressants (Supplementary information
Fig. 4). Subsequently, we adjusted the outcomes of
the inflammation indexes for multiple testing using the
Benjamin–Hochberg procedure47. Means of subscale
scores (i.e., sickness behavior vs. non-sickness behavior)
were computed and presented in line graphs for the
effects over time. In order to yield beta coefficients that
can be compared among symptoms, all outcome and
independent variables were standardized (i.e., z-scores)
with two-sided p values. All models were run in R,
version 3.4.3.
Results
Sociodemographic and clinical characteristics at baseline
Our study sample was 66.7% female (n= 1975), and the
ages ranged from 18 to 64 years at baseline (mean 42.9
years, SD 13.1; see Table 1 for demographics). The sample
consisted of 35.4% 1-month recency MDD patients (n=
796), 2.8% with minor depression (n= 84), 9.3% with
dysthymia (n= 277), 43.6% with a (comorbid) anxiety
disorder (n= 1299), and 46.1% without a mood or anxiety
diagnosis at baseline (n= 1368), of whom 54.2% never
had a psychiatric diagnosis (n= 742).
Basal inflammation
We found a small but significant association between
the basal inflammatory index and IDS-scores adjusted for
age, gender, and anti-inflammatory medication (β= 0.039;
p < 0.001). Thus, participants with a higher inflammatory
index tended to have a 0.039 SD higher IDS-30 score over
the course of 9 years, compared with participants with a
1 SD lower inflammatory index. This comes down to a
absolute value of 1.12 IDS-SR sum score.
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Next, we analyzed the associations between the basal
inflammation index for each of the 30 IDS items. Table 2
and Fig. 1 present the standardized beta coefficients of
the basal inflammation index adjusted for age, gender,
sickness prior to interview, and anti-inflammatory med-
ication. All individual symptoms were positively related
to high levels of basal inflammation. The beta sizes ran-
ged from 0.005 (Item 2: Sleep during the night) to 0.085
(Item 25: Aches and pains). The course of tertiles of mean
scores of sickness behavior symptoms vs. non-sickness
behavior symptoms is presented in Fig. 2. As expected,
both sub-scores declined steeply after baseline due to
regression to the mean effects of anxiety and MDD
patients who were initially selected for the NESDA
cohort. Symptoms related to sickness behavior more
strongly associated with basal inflammatory markers than
other symptoms, the mean scores of which remained
relatively elevated during the 9 years. Beta coefficients
were statistically significant for quality of mood (Item 10;
β= 0.028, p= 0.049) and all other items with beta coef-
ficients above 0.028 (see Fig. 1). After adjusting for
multiple testing for all tests summarized in Table 2, p
values remained statistically significant for 17 items. Of
the symptoms related to sickness behavior, 14 out of
16 symptoms were significantly associated with inflam-
mation, compared with six out of 14 non-sickness-
behavior symptoms. We found similar results with MDD
patients only (n= 908), albeit with overall weaker effects
due to lower variance and a smaller sample size (see
Supplementary information Table 1 and Supplementary
information Fig. 2). Among patients with MDD at base-
line, eight out of 16 sickness-behavior-related symptoms
were significantly associated with inflammation
Table 1 Sociodemographic and clinical characteristics.
Whole sample LPS-induced
subsample
n= 2872 n= 1229
Age in years (mean, SD) 41.9 (13.0) 42.8 (12.7)
Female (%) 66.5 65.6
North-European etnicity (%) 94.9 94.8
BMI (mean, SD) 25.6 (5.0) 25.7 (5.0)
Smoking status (%)
Never smoker 28.0 29.0
Former smoker 33.6 34.2
Current smoker 38.4 36.8
Education level (%)
Elementary or lower 6.49 6.4
Secondary education 58.2 56.7
College or university 35.4 36.9
Sickness prior to interview (%) 27.9 30.1
Chronic somatic disease, yes (%) 40.4 44.3
Anti-inflam. med., yes (%) 4.9 3.1
MDD, yes (%) 35.4 28.8
Minor depression, yes (%) 2.8 2.1
Dysthymia, yes (%) 9.3 10.4
Anxiety disorder, yes (%) 43.6 44.4
No Disorder (%) 46.1 46.3
No lifetime disorder (%) 34.1 36.3
Total score IDS at baseline (SD) 21.184 (14.6) 20.86 (14.6)
Antidepressants
TCA (%) 3.7 2.9
SSRI (%) 16.8 16.5
Other (%) 5.5 5.6
No AD (%) 75.5 75.9
Inflammatory markers (mean, sd)
TNF-α (pg/ml) 1.09 (1.41)
IL-6 (pg/ml) 1.55 (13.5)
CRP (mg/L) 2.82 (5.12)
Inflammatory markers after LPS
induction (mean, sd)
IFN-ƴ (pg/ml) 12.80 (10.8)
IL-10 (pg/ml) 300.28 (294.9)
IL-18 (pg/ml) 262.39 (91.9)
IL-2 (pg/ml) 10.06 (5.0)




n= 2872 n= 1229
IL-8 (ng/ml) 12.02 (7.7)
MCP-1 (ng/ml) 1.72 (1.1)
MIP-1α (ng/ml) 19.38 (12.0)
MIP-1β (ng/ml) 245.52 (123.3)
MMP-2 (pg/ml) 72.13 (19.3)
TNF-α (ng/ml) 3.19 (2.0)
TNF-β (pg/ml) 324.21 (126.6)
Demographic and clinical sample characteristics.
BMI body mass index, MDD major depressive disorder, TCA tricyclic antidepres-
sants, SSRI selective serotonin reuptake inhibitors, AD antidepressants, TNF
(median) tumor necrosis factor, IL Interleukin, CRP C-reactive protein, IFN-ƴ
Interferon-ƴ, MCP-1 higher monocyte chemoattractant protein-1, MIP macro-
phage inflammatory protein, MMP-2 matrix metallopeptidase-2.
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Table 2 (A) Basal serum inflammatory markers in realtion to IDS symptoms over the course of 9 years. (B) LPS-induced
inflammatory markers in realtion to IDS symptoms over the course of 9 years.
A. Basal Serum inflammation index
CRP, TNF-α, IL-6
Item Beta (SE) p value
1. Falling asleep 0.025 (0.015) 0.096
2. Sleep during the night 0.005 (0.014) 0.723
3. Waking up too early 0.015 (0.014) 0.270
4. Sleeping too much 0.053 (0.014) <0.001*
5. Feeling Sad 0.033 (0.014) 0.022*
6. Feeling irritable 0.016 (0.014) 0.252
7. Anxious or tense 0.018 (0.014) 0.213
8. Response of mood 0.038 (0.013) 0.004*
9a. Mood in time of day 0.012 (0.013) 0.361
10. Quality of mood 0.028 (0.014) 0.049*
11. Decreased appetite 0.039 (0.012) 0.001*
12. Increased appetite 0.050 (0.013) <0.001*
13. Decreased weight 0.041 (0.010) <0.001*
14. Increased weight 0.031 (0.011) 0.006*
15. Concentration 0.025 (0.014) 0.071
16. View of myself 0.034 (0.014) 0.018*
17. View of my future 0.051 (0.014) <0.001*
18. Death or suicide 0.034 (0.014) 0.017*
19. General interest 0.057 (0.014) <0.001*
20. Energy level 0.076 (0.014) <0.001*
21. Capacity for pleasure 0.057 (0.014) <0.001*
22. Interest in sex 0.053 (0.014) <0.001*
23. Psychomotor retardation 0.061 (0.014) <0.001*
24. Psychomotor agitation 0.018 (0.014) 0.220
25. Aches and pains 0.085 (0.014) <0.001*
26. Sympathetic arousal 0.055 (0.014) <0.001*
27. Panic/Phobic 0.016 (0.015) 0.288
28. Constipation/diarrhea 0.041 (0.014) 0.003*
29. Interpersonal sensitivity 0.006 (0.014) 0.683
30. Leaden paralysis 0.072 (0.014) <0.001*
B. LPS-induced index inflammation factor 1 LPS-induced index inflammation factor 2
IL-2, IL-6, IL-10, MMP-2, TNF-α, TNF-β, IFN-y IL-8, IL-18, MCP-1, MIP-1α, MIP-1β
Item Beta (SE) p value Beta (SE) p value
1. Falling asleep 0.018 (0.024) 0.445 0.013 (0.024) 0.570
2. Sleep during the night 0.032 (0.022) 0.132 0.017 (0.022) 0.429
3. Waking up too early −0.003 (0.023) 0.879 −0.004 (0.023) 0.853
4. Sleeping too much 0.010 (0.023) 0.653 0.008 (0.023) 0.720
5. Feeling Sad 0.018 (0.024) 0.466 0.028 (0.024) 0.247
6. Feeling irritable 0.049 (0.023) 0.035* 0.075 (0.023) 0.001*
7. Anxious or tense 0.045 (0.023) 0.055 0.064 (0.023) 0.007*
8. Response of mood 0.030 (0.021) 0.159 0.071 (0.021) 0.001*
9a. Mood in time of day −0.005 (0.021) 0.820 0.032 (0.021) 0.132
10. Quality of mood 0.039 (0.023) 0.093 0.071 (0.023) 0.002*
11. Decreased appetite 0.017 (0.019) 0.359 0.071 (0.018) <0.001*
12. Increased appetite −0.004 (0.021) 0.852 0.012 (0.021) 0.567
13. Decreased weight 0.003 (0.016) 0.854 0.050 (0.016) 0.002*
14. Increased weight 0.013 (0.018) 0.469 0.030 (0.018) 0.088
15. Concentration 0.024 (0.023) 0.290 0.071 (0.023) 0.002*
16. View of myself 0.006 (0.024) 0.799 0.080 (0.023) 0.001*
17. View of my future 0.042 (0.024) 0.081 0.072 (0.024) 0.003*
van Eeden et al. Translational Psychiatry          (2020) 10:235 Page 6 of 12
compared with three out of 14 non-sickness-behavior-
related symptoms.
LPS-induced inflammation
The overall LPS-induced inflammation index (β=
0.036; p= 0.014) and the LPS-induced inflammation
index-2 (β= 0.056, p < 0.001) were significantly related to
the IDS score averaged over 30 items, and the LPS-
induced inflammation index-1 indicated a relationship
that approached significance (β= 0.026; p= 0.072). In
absolute values this would translates in IDS-SR sum-
scores difference of 1.12, 0.82, 1.71 for each SD increase of
the LPS-induced inflammation index, LPS-induced
inflammation index-1, and LPS-induced inflammation
index-2, respectively.
The LPS-induced inflammation index-2 more strongly
related to sickness-behavior symptoms, compared with
non-sickness-behavior symptoms, than LPS-induced
inflammation index-1, the beta coefficients of which
ranged from −0.005 (mood related to time of the day) to
0.049 (feeling irritable) and were statistically significant
for feeling irritable (Item 6; β= 0.049, p= 0.035) and
panic/phobia (Item 27; β= 0.056, p= 0.018). After
adjusting for multiple testing, only panic/phobia remained
statistically significant.
Regarding LPS-induced inflammation index-2, beta
coefficients ranged from −0.004 (waking up too early) to
0.105 (aches and pains). Betas were statistically significant
for 13 out of 16 sickness-behavior symptoms and for six
out of 14 non-sickness-behavior symptoms, with sig-
nificant betas for decreased weight (Item 13; β= 0.050,
p= 0.002) and all other items with betas >0.050 (see
Fig. 1). Sickness-behavior symptoms remained elevated
over the 9 years (Fig. 2). After adjusting for multiple
testing, p values remained significant for 19 items.
In a sensitivity analysis, we analyzed the association of
the composite LPS-induced inflammation index for all
LPS-induced markers. Only seven out of 30 symptoms
indicated significant associations (see Supplementary
information Table 2 and Supplementary information
Fig. 3). However, findings were no longer statistically
significant after we adjusted for multiple testing. The LPS-
induced inflammation index was equally related to sick-
ness- and non-sickness-behavior symptoms.
Discussion
We aimed to examine whether diverse inflammatory
markers could predict the trajectories of individual
symptoms of depression over the course of 9 years, spe-
cifically looking at symptoms indicative of sickness
behavior. We found that the basal inflammation index and
the LPS-induced inflammation index-2 predicted many
depressive symptoms over the course of 9 years. By con-
ducting regression analysis for each individual symptom
separately, we demonstrated that significant associations
between inflammatory markers and the course of a par-
ticular individual symptom was more than twice as likely
to be significant when that symptom was related to
sickness behavior compared with non-sickness-related
behavior. The sickness-behavior theory may explain the
rather weak (or sometimes conflicting) relationships
found between low-grade inflammation and MDD18.
Four previous studies, three with cross-sectional30,31,33
and one with a prospective design34, have examined
Table 2 continued
B. LPS-induced index inflammation factor 1 LPS-induced index inflammation factor 2
IL-2, IL-6, IL-10, MMP-2, TNF-α, TNF-β, IFN-y IL-8, IL-18, MCP-1, MIP-1α, MIP-1β
Item Beta (SE) p value Beta (SE) p value
18. Death or suicide 0.041 (0.023) 0.082 0.040 (0.023) 0.082
19. General interest 0.026 (0.022) 0.242 0.068 (0.022) 0.002*
20. Energy level 0.027 (0.023) 0.233 0.085 (0.022) <0.001*
21. Capacity for pleasure 0.014 (0.023) 0.523 0.070 (0.022) 0.002
22. Interest in sex 0.000 (0.022) 0.987 0.040 (0.022) 0.070
23. Psychomotor retardation 0.013 (0.023) 0.561 0.068 (0.022) 0.003*
24. Psychomotor agitation 0.011 (0.023) 0.650 0.065 (0.023) 0.005*
25. Aches and pains 0.045 (0.023) 0.052 0.105 (0.023) <0.001*
26. Sympathetic arousal 0.025 (0.023) 0.260 0.073 (0.022) 0.001*
27. Panic/Phobic 0.056 (0.024) 0.018* 0.068 (0.024) 0.004*
28. Constipation/diarrhea 0.039 (0.022) 0.085 0.024 (0.022) 0.282
29. Interpersonal sensitivity 0.023 (0.024) 0.332 0.061 (0.023) 0.009*
30. Leaden paralysis 0.021 (0.024) 0.369 0.077 (0.023) 0.001*
Standardized beta coefficients of the association between basal serum inflammatory markers and individual depressive symptoms. Linear mixed models fitted with
repeated measures, using standardized IDS-SR item-scores as outcome variables, which were assessed up to six times over 9 years of follow-up. Standardized beta
coefficients were adjusted for gender, age, sickness prior to interview, and the use of anti-inflammatory medication.
*P values that remained significant (<0.05) after correcting for multiple testing using the Benjamin–Hochberg procedure.
van Eeden et al. Translational Psychiatry          (2020) 10:235 Page 7 of 12
symptom-specific associations between basal serum
inflammatory markers and depression. One study found
that inflammation was specifically related to a change in
appetite, poor sleep, and low energy33. Two of the cross-
sectional studies were conducted within the current
NESDA cohort and demonstrated that symptoms of
sleeping problems, energy levels, appetite/weight changes,
aches and pains and irritability were most likely to be
positively associated with basal inflammatory mar-
kers30,31. By using network analyses, it was further
demonstrated that the relation between basal inflamma-
tory markers mostly runs through, and was affected by,
lifestyle and disease-related covariates, such as BMI,
activity level, and chronic somatic diseases31. Our study
differed from these analyses because we used index scores
instead of individual inflammatory markers. Moreover, as
recommended for future research directions31,48, the
individual symptoms were measured longitudinally at six
time points over the course of 9 years. We adjusted for
two disease-related variables (sickness prior to intake, and
anti-inflammatory markers). Moreover, in a sensitivity
analysis, we additionally adjusted for the count of self-
report chronic somatic diseases and the use of anti-
depressants, which yielded a small attenuation of our
results, but did not lead to different conclusions
(Supplementary information Fig. 4). Our findings are
largely consistent with previous findings; signs of low-
grade inflammation at baseline were associated with the
long-term symptomatology of sickness behavior18, and
elevated levels of inflammation could lead to sickness
behavior, which may explain some of the symptoms in
certain cases of MDD49–51. However, we also found sig-
nificant associations with symptoms that are not typical of
sickness behavior (e.g., anxiety and low self-esteem). It is
likely that much of the associations we found runs
through lifestyle and disease-related variables, as these
factors are thought to be part of the causal pathway16,31,52.
It is hypothesized that (chronic) somatic factors results in
higher levels of inflammatory markers, which in its turn
results in sickness behavior (including lifestyle factors such
as lower activity) which is related to, and is part of the
depressive symptomatology16,31,52. Another line of thought
is that these somatic and lifestyle factors act as con-
founding variables as they are both related to inflamma-
tion and depression52. The fact that we found the strongest
association to symptoms that are specifically related to
sickness behavior over the course of 9 years, suggests
however that the sickness behavior theory is probable16,53.
To our knowledge, this is the first study that examined
LPS-induced inflammatory markers in relation to the
Fig. 1 Associations of the basal inflammation index (n= 2872), LPS-induced inflammation index-1 (n= 1147), and LPS-induced
inflammation index-2 (n= 1229) with individual depressive symptoms during 9 years. Standardized beta coefficients with error bars
representing standard errors of the predictive values of inflammatory indexes in relation to individual depressive symptoms over 9 years of follow-up.
The red dots represent depressive symptoms that are assumed to be related to sickness behavior. The blue dots represent depressive symptoms that
are not related to sickness behavior. Beta coefficients translates a “the amount of SD that particular symptom is elevated averaged over 9 years, for
each increased SD of inflammatory marker”. Assessments conducted using linear mixed models with repeated measures, adjusting for gender, age,
use of anti-inflammatory drugs, and sickness prior to interview.
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course of individual depressive symptoms. These markers
reflect the cytokine production capacity when triggered by
endogenous or exogenous triggers9,54, and are thought to
be less affected by health and lifestyle factors such as BMI
and chronic somatic diseases13. We found strong asso-
ciations between LPS-induced inflammation index-2
markers and depressive symptoms. However, LPS-
induced inflammation index-1 did not demonstrate such
results. When looking at individual symptoms, LPS-
induced, but not basal levels seem to be more specifically
associated to symptoms of anxiety. Although this was not
the focus of the current study, these findings are in line
with the idea that anxiety-related symptoms may induce
an inflammatory response13,14,21. Future research may
focus on the potential role of LPS-induced markers in
relation to the longitudinal course of anxiety-related
symptoms.
Cytokines contribute to many aspects of human biology
and have evolved to enable the sensing and interpretation
of environmental cues relevant to maintaining a healthy
physiology55. Although these secretory (glycol) proteins
are best known for their role as custodians of immune
homeostasis and the inflammatory response to infection,
trauma, or injury, this study confirms their additional
effects on mood and behavior56. Cytokines often display
heterogenetic, pleiotropic, and overlapping functional
properties57. Although cytokines are considered to be a
“family,” this is a functional (rather than structural) con-
cept. A common factor of the markers clustered in the
LPS-induced inflammation index-2 is the link with T
lymphocyte cells (T cells) and natural killer cells (NK
cells). MCP-1, MIP-1α, and MIP-1β have a signaling
function for monocytes and regulate T-cell activity. MIP-
1β has an additional specificity for NK cells. IL-8 and IL-
18 induce certain T-cell and NK-cell functions such as
chemotaxis58,59 and locomotion60,61. There are indications
that some MDD patients have impaired neuroprotective
and anti-inflammatory T-cell responses1. Also, researchers
have found a reduced number of circulating NK cells for
MDD patients compared with healthy controls1,62.
Fig. 2 Tertiles of the basal inflammation index, LPS-induced inflammation index-1, and LPS-induced inflammation index-2 related to IDS-
SR item-scores of sickness-behavior symptoms and non-sickness-behavior symptoms over the course of 9 years. Inflammation indexes are
divided into tertiles of equal proportions of the sample distribution (1. lowest inflammatory markers: 0.0–0.33; 2. middle: 0.33–0.66; 3. highest:
0.66–1.0). Y-axis represent absolute mean values of IDS-SR item-scores (0–3). Error bars representing standard errors. IDS items related to sickness
behavior: sleeping too much (Item 4), feeling irritable (Item 6), responsiveness of mood (Item 8), decrease in appetite (Item 11), decrease in weight
(Item 12), concentration (Item 15), pessimism (Item 17), general interest (Item 19), low energy level (Item 20), capacity for pleasure (Item 21), interest
in sex (Item 22), psychomotor retardation (Item 23), aches and pains (Item 25), constipation or diarrhea (Item 28) and leaden paralysis (Item 30). Non-
sickness behavior IDS items: falling asleep (Item 1), sleep during the night (Item 2), waking up too early (Item 3), feeling sad (Item 5), anxious or tense
(Item 7), mood in time of day (Item 9a), quality of mood (Item 10), increased appetite (Item 12), increased weight (Item 14), view of myself (Item 16),
death or suicide (Item 18), psychomotor agitation (Item 24), sympathetic arousal (Item 26), panic/phobic (Item 27), and interpersonal sensitivity
(Item 29).
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Depression is a heterogeneous syndrome with a sub-
stantial variety of symptoms among patients with
symptom-specific risk factors63. Not all patients exhibit
symptoms related to sickness behavior, and only one-third
of MDD patients exhibit elevated inflammatory mar-
kers64. Our findings could have implications for anti-
inflammatory treatment6,65 and preventative care66–69 in a
subgroup of depressed patients with sickness-behavior-
related symptoms70. Research is underway to investigate
the effects of anti-TNF-alpha biologic infliximab on
measures of anhedonia, motivational behavior, and glu-
tamatergic changes in the basal ganglia71 and to investi-
gate the effects of simvastatin for treatment-resistant
MDD72 and patients with comorbid obesity and MMD73.
We recommend that future studies approach depression
as a group of separate symptoms rather than as a unified
construct. The construct of sickness behavior could be
particularly promising in this regard.
Our study features several strengths, namely the sub-
stantial sample size and the 9-year follow-up period
wherein we analyzed individual symptoms of depression.
Multiple reviews have published about the sickness
behavior theory and how this could relate to symptoms of
depression. However, not many papers exist that tested
how this theory translates to data of self-report symptoms
of depression1–5. “This” study is novel in the sense that we
explicitly categorized symptoms into sickness behavior
symptoms and non-sickness behavior symptoms and
found a convincing stronger association with the first.
Moreover, a wide array of inflammatory markers were
assessed at baseline, including LPS-induced markers. We
did not have preliminary hypotheses regarding which
markers would indicate certain depressive symptoms, so
we constructed three inflammatory indexes based on
inflammatory markers to enhance the interpretability of
our results. We demonstrated the utility of these index
scores for research purposes and it’s potential for clinical
practice. By averaging multiple markers the effect of
individual measurement errors is reduced, which is an
important methodological advantage74. Some limitations
must also be discussed. First, some of the component
markers of the index scores were only weakly inter-
correlated. Moreover, we composed two indexes based on
data driven methods (Factor analysis44), more research is
needed regarding grouping of individual markers based
on underlying properties. Second, we repeatedly use the
ill-defined term “sickness behavior”; different fields of
medicine should solidify the definition so as to develop
this construct in more depth17,18. Third, due to logistical
reasons, LPS-stimulated markers were only assessed in a
consecutive subsample of 1229 participants. Fourth, pre-
vious studies found that antidepressants might have anti-
inflammatory effects. Rats treated with fluoxetine
demonstrated lower IL-1β in plasma and brain after 90
and 120-day treatment75. Furthermore, two meta-analyses
demonstrated that among MDD patients antidepressant
treatment decreases TNF-α, IL-4, IL-6, IL-10 and
IL-1ß76,77. In the present study, the use of antidepressants
was not adjusted for in our first models, as their use may
indicate more severe depressive symptoms (confounding-
by-indication) and therefore may lead to overadjustment.
However, sensitivity analyses demonstrate adding this
variable as a confounder had only a limited effect on our
outcomes and conclusions (Supplementary information
Fig. 4). Finally, beta coefficients were statistically sig-
nificant but still of small effect sizes, with questionable
clinical relevance. However, self-reported IDS items were
scored on crude four-point scales, potentially contributing
to measurement error and reduced statistical power.
Moreover, the NESDA cohort only used a single mea-
surement of inflammatory markers; trajectory analyses
with sequential day-to-day measures of inflammatory
markers would have increased the precision of the inde-
pendent variable.
In conclusion, we found that basal levels of inflamma-
tion and LPS-induced inflammatory markers predicted
the course of individual depressive symptoms, especially
those related to the construct of sickness behavior. This
association persisted over the course of 9 years. Our
findings suggest that inflammation might not relate to
depression as one unified syndrome but rather to the
presence and course of a subset of symptoms. Future
studies should develop inflammation-targeted treatment
strategies for individuals with symptom profiles associated
with low-grade inflammation.
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